Silence Therapeutics’ (SLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

A number of other equities analysts have also issued reports on the company. Chardan Capital reaffirmed a buy rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Friday, August 16th. Morgan Stanley raised their price objective on Silence Therapeutics from $45.00 to $49.00 and gave the stock an overweight rating in a research note on Friday, June 28th.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $19.09 on Friday. The stock has a fifty day moving average price of $18.70 and a two-hundred day moving average price of $20.98. The firm has a market cap of $571.33 million, a P/E ratio of -16.46 and a beta of 1.30. Silence Therapeutics has a 1 year low of $6.15 and a 1 year high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $11.28 million. Silence Therapeutics had a negative net margin of 222.44% and a negative return on equity of 58.28%. On average, research analysts predict that Silence Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Large investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of Silence Therapeutics in the second quarter worth $114,000. SG Americas Securities LLC boosted its position in Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after purchasing an additional 667 shares during the last quarter. Custom Index Systems LLC acquired a new stake in Silence Therapeutics during the second quarter valued at $282,000. Legato Capital Management LLC acquired a new stake in Silence Therapeutics during the second quarter valued at $376,000. Finally, Point72 Asset Management L.P. boosted its position in Silence Therapeutics by 1,686.6% during the second quarter. Point72 Asset Management L.P. now owns 146,500 shares of the company’s stock valued at $2,784,000 after purchasing an additional 138,300 shares during the last quarter. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.